



Cohen, J. B., Brown, N. J., Brown, S.-A., Dent, S., van Dorst, D. C.H., Herrmann, S. M., Lang, N. N. , Oudit, G. Y. and Touyz, R. M. (2023) Cancer therapy–related hypertension: a scientific statement from the American Heart Association. *Hypertension*, 80(3), e46-e57. (doi: [10.1161/HYP.0000000000000224](https://doi.org/10.1161/HYP.0000000000000224))

The material cannot be used for any other purpose without further permission of the publisher and is for private use only.

There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it.

<https://eprints.gla.ac.uk/289429/>

Deposited on 11 January 2023

Enlighten – Research publications by members of the University of  
Glasgow

<http://eprints.gla.ac.uk>

## 1 AHA Scientific Statement

2 **Cancer Therapy-Related Hypertension**

3 A Scientific Statement from the American Heart Association

4 Jordana B. Cohen MD, MSCE (Vice Chair)<sup>1</sup>; Nancy J. Brown MD<sup>2</sup>; Sherry-Ann Brown MD,  
5 PhD<sup>3</sup>; Susan Dent MD<sup>4</sup>; Daan C. H. van Dorst MD, MSc<sup>5</sup>; Sandra M. Hermann MD<sup>6</sup>; Ninian N.  
6 Lang, MD, PhD<sup>7</sup>; Gavin Y. Oudit, MD, PhD<sup>8</sup>; Rhian M. Touyz, MD, PhD<sup>9</sup> (Chair); on behalf of  
7 the American Heart Association Council on Hypertension, Council on Arteriosclerosis,  
8 Thrombosis and Vascular Biology, and Council on the Kidney in Cardiovascular Disease  
9

10 <sup>1</sup>. Renal-Electrolyte and Hypertension Division and Department of Biostatistics, Epidemiology,  
11 and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA,  
12 USA; <sup>2</sup>. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; <sup>3</sup>.  
13 Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA; <sup>4</sup>. Duke Cancer  
14 Institute, Duke University, Durham, NC, USA; <sup>5</sup>. Divisions of Pharmacology, Vascular  
15 Medicine, and Medical Oncology, Department of Internal Medicine, Erasmus University  
16 Medical Center, Rotterdam, Netherlands; <sup>6</sup>. Nephrology and Hypertension Division, Mayo  
17 Clinic, Rochester, MN, USA; <sup>7</sup>. Institute of Cardiovascular and Medical Sciences, University of  
18 Glasgow, Glasgow, UK. ; <sup>8</sup>. Division of Cardiology, Department of Medicine, University of  
19 Alberta, Edmonton, Alberta, Canada; <sup>9</sup>. Research Institute of the McGill University Health  
20 Centre, McGill University, Montreal, Quebec, Canada

21  
22 **Short title:** Anti-cancer drugs and hypertension  
23

1 **Key words:** cardio-oncology, cardiovascular toxicities, blood pressure, anti-angiogenesis,  
2 tyrosine kinase inhibitors.

3

4 **Word count:** 3997 excluding abstract, affiliations, references, conflicts and acknowledgements

5

6

**1 ABSTRACT**

2 Contemporary anti-cancer drugs have significantly improved cancer survival at the expense of  
3 cardiovascular toxicities, including heart disease, thromboembolic disease and hypertension. One  
4 of the most common side effects of these drugs is hypertension, especially in patients treated  
5 with vascular endothelial growth factor inhibitors, as well as tyrosine kinase inhibitors and  
6 proteasome inhibitors. Adjunctive therapy including corticosteroids, calcineurin inhibitors and  
7 non-steroidal anti-inflammatories, as well as anti-androgen hormone therapy for prostate cancer  
8 may further increase blood pressure in these patients. Cancer therapy-induced hypertension is  
9 often dose-limiting, increases cardiovascular mortality in cancer survivors, and is usually  
10 reversible after interruption or discontinuation of treatment. Exact molecular mechanisms  
11 underlying hypertension are unclear, but recent discoveries indicate an important role for  
12 reduced nitric oxide generation, oxidative stress, endothelin-1, prostaglandins, endothelial  
13 dysfunction, increased sympathetic outflow, and microvascular rarefaction. Additionally, genetic  
14 polymorphisms in vascular endothelial growth factor receptors are implicated in vascular  
15 endothelial growth factor inhibitor-induced hypertension. Diagnosis, management and follow-up  
16 of cancer therapy-induced hypertension follow national hypertension guidelines, since evidence-  
17 based clinical trials specifically addressing patients who develop hypertension due to cancer  
18 therapy, are currently lacking. Rigorous baseline assessment of patients prior to commencing  
19 therapy requires particular emphasis on assessing and treating cardiovascular risk factors.  
20 Hypertension management follows guidelines for the general population, although special  
21 attention should be given to rebound hypotension following termination of cancer therapy.  
22 Management of these complex patients requires collaborative care involving oncologists,

1 cardiologists, hypertension specialists, primary care providers and pharmacists to ensure optimal  
2 therapeutic effect from cancer treatment while minimizing competing cardiovascular toxicities.

3

4

## 1 INTRODUCTION

2 Hypertension is more common in patients on anti-cancer therapy than the general population due  
3 to multiple mechanisms, including direct vascular and renal effects of anti-cancer therapy.  
4 Hypertension and blood pressure (BP) lability begin at the time of initiation of anti-cancer  
5 therapy and continue lifelong, which can result in interruptions in treatment and place patients at  
6 increased risk of cardiovascular disease (CVD) and mortality.<sup>1</sup> Many contemporary cancer  
7 therapies are associated with cardiovascular-toxicity leading to heart disease, thromboembolic  
8 disease, and hypertension. Management of hypertension in patients on anti-cancer therapy is  
9 largely empiric, with no current trial data supporting specific agents or treatment goals in this  
10 distinctive population. This paper provides an overview of the mechanisms and clinical  
11 management of anti-cancer therapy-induced hypertension.

12

## 13 EPIDEMIOLOGY

### 14 *Hypertension and cancer as major causes of global morbidity and mortality*

15 Cancer and CVD are major causes of morbidity and mortality globally.<sup>2</sup> Hypertension is one of  
16 the main risk factors for the development of CVD, including ischemic heart disease, heart  
17 failure, stroke, and kidney disease. The prevalence of hypertension worldwide is increasing,  
18 reaching 1.3 billion in adults in 2019.<sup>3</sup> Despite availability of effective antihypertensive drugs,  
19 BP is inadequately controlled in almost 50% of those known to have hypertension. The current  
20 definitions of normal BP, elevated BP, and hypertension, based on the 2017 American College of  
21 Cardiology (ACC)/American Heart Association (AHA) guidelines as well as other major  
22 guidelines are presented in **Table 1**.<sup>4</sup> The incidence of cancer is also increasing. The Global

1 Cancer Observatory estimates that the number of new cancer cases worldwide will increase from  
2 19.3 million in 2020 to >28 million in 2040.<sup>5</sup>

3

#### 4 ***Common risk factors of hypertension and cancer***

5 A bidirectional relationship between cancer and hypertension has been proposed. Hypertension is  
6 associated with an increased risk of cancer. This is most clearly displayed by the increased risk  
7 of renal cell carcinoma in patients with hypertension.<sup>6</sup> Additionally, the prevalence of  
8 hypertension is higher in patients with cancer and cancer survivors than in the general  
9 population.<sup>1</sup> A prospective cohort study of >17,000 patients with cancer found that hypertension  
10 was the most common comorbidity (38% prevalence).<sup>7</sup> The frequent concurrence of cancer and  
11 hypertension and the increased cardiovascular risk in patients with cancer are most likely  
12 explained by the presence of common risk factors and pathophysiological mechanisms, including  
13 smoking, diabetes, chronic kidney disease, physical inactivity, obesity, oxidative stress, and  
14 inflammation.<sup>8-10</sup> CVD morbidity and mortality are increased in patients with cancer and cancer  
15 survivors.<sup>11</sup> In addition, many anti-cancer drugs cause BP elevation through numerous  
16 mechanisms.

17

#### 18 **ANTI-CANCER DRUGS THAT CAUSE HYPERTENSION AND POTENTIAL** 19 **MECHANISMS**

##### 20 ***Vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSPIs)***

21 VSPIs exert their anti-cancer effects by inhibition of VEGF-mediated tumor angiogenesis,  
22 depriving tumor cells of oxygen and nutrient supply. These agents act via inhibition of VEGF  
23 directly or by inhibition of tyrosine kinase receptors (**Table 2**). As recently reviewed by

1 Camarda et al.,<sup>12</sup> they have well-established treatment efficacy in numerous cancers, especially  
2 renal, hepatocellular, thyroid, gastrointestinal stromal and others.

3 VSPIs are associated with adverse cardiovascular effects, of which hypertension is the  
4 most frequent. They cause an acute increase in BP that is sustained during treatment in the  
5 majority of patients. The reported incidence of VSPI-induced hypertension ranges from 20%-  
6 90% and varies with VSPI potency and dosage as well as methods and definitions for reporting  
7 BP.<sup>8</sup> In a meta-analysis of 29,000 patients with cancer, there was a 3.8-fold higher relative risk  
8 for hypertension in those treated with a VEGF tyrosine kinase inhibitor (TKI) compared to  
9 controls (**Table 2**).<sup>13</sup> VSPI-associated hypertension is reversible and resolves upon  
10 discontinuation of the agent, indicating an ‘on-target’ effect. Accordingly, VSPI-induced  
11 hypertension has been suggested as a predictor or biomarker of therapeutic efficacy.<sup>14</sup>

12 VEGF is a potent vasodilator and its absence is associated with reduced bioavailability of  
13 the vasodilator nitric oxide (NO) and increased concentrations of the potent vasoconstrictor,  
14 endothelin-1, important in hypertension pathophysiology (**Figure 1**). VEGF signalling pathway  
15 inhibition is also associated with increased generation of reactive oxygen species (ROS),  
16 including reactive nitrogen species, H<sub>2</sub>O<sub>2</sub>, and O<sub>2</sub><sup>-</sup>, causing vascular oxidative stress.<sup>15</sup>  
17 Rarefaction (reduced microvascular density) occurs (previously observed in the skin and oral  
18 mucosa), with a consequent increase in vascular resistance thought to lead to elevated BP.<sup>16</sup>  
19 VSPIs are associated with nephrotoxicity, which may also contribute to their prohypertensive  
20 effects via impaired natriuresis.<sup>8</sup> Current evidence does not suggest a major role for the renin-  
21 angiotensin-aldosterone system in the pathophysiology of VSPI-associated hypertension. VSPIs  
22 also interfere with other growth factor pathways, including platelet-derived growth factor,



1 fibroblast growth factor, fms-like tyrosine kinase 3 and c-Kit. Inhibition of these pathways  
2 evokes further potential prohypertensive mechanisms.<sup>8</sup>

3

4 ***Rapidly accelerated fibrosarcoma B-type (BRAF) and mitogen-activated kinase kinase (MEK)***  
5 ***inhibitors***

6 BRAF/MEK inhibitors are used in the treatment of BRAF-mutant melanoma and BRAF mutant  
7 colorectal cancer.<sup>17</sup> These agents are frequently prescribed in combination. Approximately 60%  
8 of patients with melanoma harbor a BRAF gene mutation with subsequent dysregulation of the  
9 Raf-MEK-extracellular signal-regulated kinases signaling pathway (**Table 2**). These pathways  
10 are also necessary for normal vascular and cardiac physiology.

11 Hypertension is the most common adverse cardiovascular event reported with  
12 BRAF/MEK inhibitors.<sup>17</sup> A meta-analysis including 5 randomized clinical trials (RCTs) reported  
13 an increased risk of systemic hypertension, which occurred in 19.5% of patients treated with  
14 combined BRAF/MEK inhibitors and 14% of those treated with BRAF inhibitor monotherapy.<sup>18</sup>  
15 BRAF/MEK inhibitor-associated hypertension may be a consequence of reduced NO  
16 bioavailability. Inhibition of BRAF and MEK is associated with upregulation of expression of  
17 Cluster of Differentiation 47 in melanoma cells in vitro. Cluster of Differentiation 47 inhibits  
18 NO/cyclic guanosine monophosphate signaling via thrombospondin-1, leading to a reduction in  
19 NO bioavailability with consequent vasoconstriction and hypertension.<sup>18</sup>

20

21 ***Bruton's tyrosine kinase inhibitors***

22 Bruton's TKIs are used in the treatment of chronic lymphocytic leukemia and mantle cell  
23 lymphoma. Ibrutinib has variable prohypertensive effects. In a study of 562 patients, treatment

1 with ibrutinib was associated with new-onset hypertension in 71% of patients with normal BP at  
2 baseline, and with worsening of preexisting hypertension in 83%.<sup>19</sup> A meta-analysis including  
3 2,580 participants revealed a 2.8-fold increased risk for hypertension in patients treated with  
4 ibrutinib.<sup>19</sup> Given that both hypertension and Bruton's TKIs increase the risk of atrial fibrillation,  
5 the prohypertensive effect of these drugs is of added significance.<sup>19</sup> Patients are frequently  
6 treated with Bruton's TKIs for many years and therefore the life-time risk of exposure to the  
7 prohypertensive effects is especially relevant. Mechanisms underpinning Bruton's TKI-  
8 associated hypertension are unclear, but a decrease in heat shock protein 70 signaling and  
9 inhibition of phosphatidylinositol 3-kinase-dependent NO production may be important.<sup>8</sup>

10

#### 11 ***Rearranged during transfection receptor (RET)-TKIs***

12 RET-TKIs are indicated for the treatment of non-small cell lung cancer and thyroid cancer with  
13 an activating mutation in the RET proto-oncogene. In a study of 162 patients with thyroid cancer  
14 treated with selpercatinib, 43% developed hypertension and 21% had BP >160/100 mmHg.<sup>20</sup> In  
15 the ARROW RCT examining pralsetinib in non-small cell lung cancer, 21% of those treated with  
16 pralsetinib developed hypertension.<sup>21</sup> Mechanisms underlying the prohypertensive effects of  
17 RET-TKIs are unknown.

18

#### 19 ***Poly adenosine diphosphate ribose polymerase inhibitors***

20 Poly adenosine diphosphate ribose polymerase inhibitors are used in the treatment of breast and  
21 ovarian cancer with BReast CAncer (BRCA) mutation. In this drug class, only niraparib has been  
22 associated with prohypertensive effects. In the NOVA RCT of niraparib in recurrent ovarian  
23 cancer, 19% patients treated with niraparib developed hypertension, versus 5% of patients

1 receiving placebo.<sup>22</sup> In the recent NORA RCT (niraparib maintenance therapy in patients with  
2 platinum-sensitive recurrent ovarian cancer using an individualized starting dose), hypertension  
3 occurred in 11% of patients treated with niraparib, compared with only 1% of patients receiving  
4 placebo.<sup>23, 24</sup> When niraparib was given in combination with the VSPI bevacizumab for ovarian  
5 cancer, hypertension occurred in 56% of patients.<sup>23, 24</sup> The mechanisms underlying niraparib-  
6 induced hypertension remain unclear.<sup>8</sup>

7

### 8 *Proteasome inhibitors*

9 Proteasome inhibitors (bortezomib, carfilzomib and ixazomib) have become the cornerstone of  
10 therapy for multiple myeloma. Cardiovascular adverse events occur with all proteasome  
11 inhibitors, but are mostly associated with carfilzomib.<sup>25</sup> In the carfilzomib and dexamethasone  
12 versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma  
13 (ENDEAVOR) trial, hypertension developed in 32% of patients receiving carfilzomib compared  
14 to 10% receiving bortezomib.<sup>26</sup> In a prospective study of 70 patients with multiple myeloma  
15 treated with carfilzomib, 33% developed adverse cardiovascular events, 91% of whom had  
16 uncontrolled hypertension.<sup>27</sup> Hypertension often reverses after discontinuation of these agents.

17 Proteasome inhibitors mediate oxidative stress by increasing ROS production and  
18 suppressing antioxidant pathways. By binding to the 20S proteolytic core of the proteasome and  
19 thereby inhibiting its catalytic activity, proteasome inhibitors lead to an intracellular  
20 accumulation of aggregated proteins that can be toxic to malignant cells.<sup>28</sup> This also has adverse  
21 cardiovascular effects, including endothelial dysfunction and reduced NO bioavailability.<sup>28</sup> Pre-  
22 existing vascular risk factors and anti-cancer therapies associated with oxidative stress make the  
23 vasculature more vulnerable to these adverse effects.<sup>29</sup>

1

## 2 *Platinum-based compounds*

3 Platinum-based compounds (cisplatin, carboplatin, oxaliplatin) are used to treat testicular,  
4 bladder, gynecological, breast, colorectal and lung cancers, as well as mesothelioma. Their anti-  
5 cancer effects result from platinum uptake to DNA with consequent apoptotic cell death.  
6 Hypertension is associated with exposure to platinum-based compounds but tends to be a late  
7 effect, which can occur many years after treatment of the index cancer. Platinum-based  
8 chemotherapy is associated with excellent long-term survival for patients with testicular cancer,  
9 the most common cancer in young men. In a study of testicular cancer survivors with a median  
10 follow-up of 11 years, hypertension was observed in 53% of those treated with cisplatin and was  
11 2.3 times more frequent than in healthy controls.<sup>30</sup>

12 Cisplatin is detected in the circulation even after 13 years post-drug exposure and this  
13 may be responsible for chronic endothelial injury and dysfunction. Increased circulating  
14 platinum concentrations are associated with an increased risk of hypertension.<sup>31</sup> Proximal tubular  
15 renal cells are the major site for cisplatin-induced renal injury, and accumulation of cisplatin in  
16 the kidney can reach levels five times higher than the serum concentration.<sup>32</sup> Cisplatin  
17 nephrotoxicity is dose-dependent and has been attributed to cellular mitochondrial damage,  
18 oxidative stress, apoptosis, and decreased NO bioavailability.<sup>33</sup>

19

## 20 *Alkylating agents*

21 Alkylating antineoplastic agents such as busulfan, ifosfamide and cyclophosphamide are used in  
22 the treatment of hematologic malignancies and solid organ malignancies. These are classical

1 chemotherapeutic agents that have been previously linked to hypertension; however,  
2 concomitant use of glucocorticoids may be a confounding factor in these observations.

3 Busulfan is mainly used as part of a pre-transplant conditioning regimen for both  
4 pediatric and adult patients with hematological malignancies. Hypertension has been noted in up  
5 to 36% of adults treated with busulfan and in up to 58% of children.<sup>10</sup> The prevalence of  
6 hypertension after ifosfamide was reported to be 15% at 5 years of follow-up in a childhood  
7 cancer survivorship study.<sup>34</sup>

8 In cyclophosphamide-treated patients with breast cancer, reduced VEGF concentrations  
9 have been demonstrated with associated endothelial dysfunction. These processes can explain, in  
10 part, the development of hypertension in patients on cyclophosphamide.<sup>35</sup> In addition, direct  
11 vascular toxicity and nephrotoxicity may contribute to the prohypertensive effects of these  
12 agents.<sup>36</sup>

13

#### 14 *Calcineurin inhibitors (CNIs)*

15 CNIs such as tacrolimus and cyclosporin are often administered concurrently with other cancer  
16 agents, mainly after hematopoietic stem cell transplantation to prevent or treat graft versus host  
17 disease.<sup>37</sup> CNIs contribute to the development of hypertension or worsening BP control in  
18 patients with a history of hypertension.<sup>38</sup> In patients undergoing bone marrow transplantation,  
19 there was a 30-60% increase in the rate of hypertension diagnoses after cyclosporin became the  
20 mainstay of treatment.<sup>39</sup> CNIs cause widespread vasoconstriction, with activation of the renin-  
21 angiotensin-aldosterone system, oxidative stress, an increase in endothelin-1 generation and  
22 sympathetic nervous system activity.<sup>40</sup> In addition, they inhibit NO synthesis and NO-mediated  
23 vasodilation.<sup>41</sup>

1

**2 *Mammalian target of rapamycin (mTOR) inhibitors***

3 Inhibitors of mTOR, including everolimus and sirolimus, are third-line treatment options for  
4 renal cell carcinoma. In a RCT including patients with metastatic renal cell carcinoma ,  
5 everolimus was associated with a 10% incidence of hypertension.<sup>8</sup> *In vitro* studies in  
6 predominantly tumor cell lines show decreased VEGF secretion upon mTOR inhibition. Thus,  
7 inhibition of mTOR may have prohypertensive effects similar to VSPIs.<sup>41</sup> The combination of  
8 everolimus with the VSPI lenvatinib was associated with hypertension in 41% of patients and  
9 high-grade hypertension in 14%, higher than either medication alone.<sup>41</sup>

10

**11 *Endocrine therapy (anti-androgens/aromatase inhibitors)***

12 Survival for patients with metastatic prostate cancer is improved by androgen deprivation  
13 therapy. These agents block the trophic effects of androgens on prostate cancer cells.  
14 Gonadotropin-releasing hormone agonists directly inhibit androgen production and signaling and  
15 are associated with potentially adverse cardiovascular effects including elevation of serum lipid  
16 levels, decreased insulin sensitivity and obesity. Abiraterone, an inhibitor of androgen synthesis  
17 and enzalutamide, an androgen receptor antagonist, are both associated with hypertension.<sup>8, 42</sup>  
18 Abiraterone inhibits testosterone production via inhibition of the cytochrome P450 enzyme with  
19 consequent accumulation of mineralocorticoid precursors. This effect contributes to its  
20 prohypertensive effects.<sup>42</sup> Mechanisms underlying enzalutamide-induced hypertension are  
21 unclear.

22 The cardiovascular toxic effects of abiraterone and enzalutamide were evaluated in a  
23 meta-analysis of 8660 patients with prostate cancer. All-grade and high-grade hypertension were

1 observed more frequently in the abiraterone group (26% and 7%, respectively) compared with  
2 placebo (15% and 4%, respectively). Similar results were reported with enzalutamide (11% and  
3 5%, respectively) compared with placebo (4% and 2%, respectively).<sup>42</sup> These rates of  
4 hypertension occurred irrespective of corticosteroid use, which is often administered  
5 concomitantly.<sup>8,42</sup>

6 Aromatase inhibitors including nonsteroidal (anastrozole and letrozole) and steroidal  
7 (exemestane) formulations, reduce breast cancer-related mortality in post-menopausal women  
8 with estrogen positive breast cancer.<sup>43, 44</sup> The association between aromatase inhibitors and  
9 cardiovascular risk is controversial with some studies identifying increased risk of hypertension  
10 and cardiovascular-related mortality.<sup>8,43</sup>

11

### 12 *Adjunctive Therapies Used in Cancer Management*

13 In addition to the BP effects associated with the specific anti-cancer drugs outlined above, many  
14 other agents prescribed for patients with cancer can contribute to unwanted BP effects.  
15 Corticosteroids are a frequent component of contemporary cancer treatment regimens and often  
16 used in supportive care management. Corticosteroids can provoke a substantial rise in BP, in  
17 isolation, and in the context of other prohypertensive therapies. Similarly, exogenous  
18 erythropoietin and non-steroidal anti-inflammatory drugs frequently cause BP elevation.<sup>8</sup>

19

## 20 **DIAGNOSIS AND MANAGEMENT OF ANTI-CANCER THERAPY-INDUCED** 21 **HYPERTENSION**

22 *Diagnosis of hypertension in anti-cancer therapy-induced hypertension.*

1 Accurate measurement of BP is crucial for hypertension diagnosis and management and special  
2 attention should be given to optimal control of anxiety and pain in patients with cancer. In  
3 general, patients should be seated quietly for 3-5 minutes before any measurement is taken, the  
4 patient's bladder should be empty, and they should have abstained from exercise and  
5 consumption of caffeine or smoking for 30 minutes.<sup>4</sup> The legs should touch the floor and not be  
6 crossed and the back should be well supported. The arm used for BP measurement should be in a  
7 resting position at the level of the heart. A calibrated and validated automated office BP device  
8 and a proper cuff size should be used.<sup>10</sup> At least 2-3 BP readings should be obtained and  
9 averaged. Elevated BP readings should be verified on at least 1 more occasion prior to a  
10 diagnosis of hypertension.<sup>4, 45</sup> 24-hour ambulatory BP monitoring is recommended for  
11 confirmation after initial readings of an elevated BP but is not always feasible. Home BP  
12 monitoring (self-monitoring of BP) with a validated device should be used in situations where  
13 frequent BP measurements over longer time periods are required, e.g. during treatment initiation  
14 or dose changes in patients receiving VSPIs wherein worsening hypertension often occurs in  
15 days and can progress to hypertensive emergency.<sup>46, 47</sup> Baseline measurement before the  
16 initiation of prohypertensive anti-cancer therapies is mandatory, as some patients may present  
17 with a notable rise in BP while on these agents requiring prompt initiation or escalation of  
18 antihypertensive therapy.

19

### 20 ***Blood Pressure targets***

21 Patients with cancer are frequently underrepresented or excluded from major cardiovascular or  
22 hypertension RCTs. RCTs are needed to define BP targets either in the context of specific anti-  
23 cancer therapies, or in patients with cancer in general. Defining BP goals for treatment and



1 diagnosis in patients with cancer therefore is an important unmet need. The definition of  
2 hypertension varies between guidelines (**Table 1**). Based on the AHA/ACC guidelines, BP is  
3 categorized as normal, elevated, stage 1, or stage 2 hypertension. Normal BP is defined as  
4  $<120/<80$  mm Hg; elevated BP as  $120-129/<80$  mm Hg; hypertension stage 1 as systolic BP  $130-$   
5  $139$  or diastolic BP  $80-89$  mm Hg, and hypertension stage 2 as  $\geq 140$  or  $\geq 90$  mm Hg.<sup>4</sup> For  
6 patients with atherosclerotic CVD 10-year risk  $\geq 10\%$ , or comorbidities such as chronic kidney  
7 disease and diabetes mellitus, treatment should be initiated in stage 1 hypertension. For others,  
8 treatment should be initiated in stage 2. The goal BP is  $<130/80$  mmHg for all individuals. To  
9 date there are no specific hypertension guidelines for patients with cancer, although the  
10 International Cardio-Oncology Society recently published a consensus statement on the  
11 definition of hypertension in cancer, representing a multidisciplinary effort.<sup>47</sup> The treatment  
12 threshold is defined as in the AHA/ACC recommendations, and treatment goals match the  
13 treatment threshold. The threshold for recommending withholding anti-cancer therapy is systolic  
14 BP  $\geq 180$  mmHg or diastolic BP  $\geq 110$  mmHg, which is similar to the hypertensive crisis  
15 definition in the AHA/ACC guidelines ( $\geq 180$  mmHg systolic and  $\geq 120$  mmHg diastolic).

16

### 17 *Management of hypertension in anti-cancer therapy-induced hypertension*

#### 18 *Antihypertensive Medications*

19 Among patients with hypertension, antihypertensive therapy should be optimized prior to  
20 initiation of anti-cancer therapy, preferably with multi-disciplinary input from the cardio-  
21 oncology care team (**Figure 2**). Patients should be counseled on the potential need to escalate  
22 antihypertensive treatment quickly if potentially pro-hypertensive anti-cancer therapy is  
23 scheduled. Insufficient evidence exists supporting a specific antihypertensive medication strategy

1 specific to patients with anti-cancer therapy-induced hypertension. Therefore, antihypertensive  
2 management should reflect current guidelines for the general population.<sup>4, 48</sup> First-line therapy  
3 should include an angiotensin receptor blocker or angiotensin-converting enzyme inhibitor,  
4 dihydropyridine calcium channel blocker, or thiazide or thiazide-like diuretic.<sup>48</sup> Selection of  
5 antihypertensive therapy should otherwise be informed by individual patient risk factors. For  
6 example, patients with proteinuria should be treated with an angiotensin receptor blocker or  
7 angiotensin-converting enzyme inhibitor<sup>45, 48</sup>; those at high risk of volume depletion should  
8 avoid use of diuretics.<sup>10</sup> As with the general population, mineralocorticoid receptor antagonists  
9 should be the initial agent of choice for the treatment of resistant hypertension, unless there is a  
10 contraindication such as hyperkalemia.<sup>4, 49</sup> Beta-blockers should not be used as first-line  
11 antihypertensive therapy, and should be reserved for individuals with a specific indication for  
12 their use (e.g., atrial fibrillation, recent myocardial infarction, heart failure with reduced ejection  
13 fraction), who are already optimized on maximum tolerated doses of first-line antihypertensive  
14 agents, or with contraindications to first-line antihypertensive agents.<sup>4, 45</sup> Non-dihydropyridine  
15 calcium channel blockers (e.g., diltiazem, verapamil) should be used with caution in this patient  
16 population, as these antihypertensive agents are susceptible to interactions with several anti-  
17 cancer therapies that are metabolized by P-glycoprotein and cytochrome P450 3A4.<sup>50</sup>

18

### 19 *Lifestyle Modifications*

20 Patients should be counseled on important lifestyle modifications that can help to improve BP  
21 control, including limiting sodium intake (with consideration for risk of hypovolemia), non-  
22 steroidal anti-inflammatory drug use, caffeine use, and alcohol use and increasing physical  
23 activity and potassium intake.<sup>4, 45, 49</sup> When evaluating patients for rising BP during anti-cancer

1 therapy, providers should address the potential role of inadequate pain control and concomitant  
2 therapies that may exacerbate hypertension, such as erythropoietin stimulating agents and  
3 corticosteroids. Evaluation of co-morbidities that may increase BP (e.g., obstructive sleep apnea)  
4 is also important.

5

### 6 *Long-term management of cancer drug-induced hypertension in cancer survivors*

7 After completing anti-cancer therapy with agents known to increase BP, patients may need to  
8 reduce antihypertensive treatment to avoid rebound hypotension and ischemic events. In patients  
9 treated with anti-cancer therapy requiring significant escalation of antihypertensive therapy at the  
10 onset, reduction in antihypertensive therapy may need to occur within days of cessation of  
11 treatment, and daily home BP monitoring may be necessary. Over the long-term, the prevalence  
12 of hypertension in cancer survivors is higher than in the general population.<sup>1</sup> Therefore, cancer  
13 survivors are likely to benefit from closer monitoring for the development of hypertension than  
14 the general population, including a combination of in-office and home BP monitoring. Similar to  
15 patients undergoing active anti-cancer therapy, there is insufficient evidence to support a specific  
16 or targeted approach to managing hypertension in cancer survivors. Therefore, these patients  
17 should be treated based on current best evidence for the general population.<sup>4, 45, 49</sup>

18

### 19 **CLINICAL PEARLS**

- 20 • Many anti-cancer drugs have cardiovascular toxicities including hypertension.
- 21 • Cancer therapy-induced hypertension, especially by VSPIs and proteasome inhibitors, is  
22 often reversible after discontinuation of these agents.
- 23 • Many anti-cancer drugs may worsen BP control in patients with existing hypertension.

- 1       • Hypertension control is important prior to, during, and following completion of cancer  
2       treatment.
- 3       • At least weekly BP monitoring is suggested for the first 4-8 weeks on cancer drugs that  
4       increase BP and upon discontinuing these drugs, given distinct risk of BP lability;  
5       holding parameters and atypical dosing of antihypertensive medications may be  
6       necessary.
- 7       • Home BP monitoring should be encouraged.
- 8       • Cancer survivors are at increased risk of hypertension-associated complications such as  
9       atrial fibrillation, heart failure, and chronic kidney disease, necessitating a  
10      multidisciplinary approach for optimal management.

11

12

### 13   **KEY GAPS AND UNMET NEEDS**

14   Gaps in knowledge remain in our understanding of the epidemiology of concomitant  
15   hypertension and cancer, especially regarding common risk factors. While these conditions are  
16   both more prevalent with aging, age alone does not seem to be the link between hypertension and  
17   cancer. Contributing to the clinical burden of co-morbidity, many anti-cancer drugs themselves  
18   cause hypertension especially VSPIs, BRAF/MEK inhibitors, BTK inhibitors, RET-TKIs, some  
19   poly adenosine diphosphate ribose polymerase inhibitors, and mTOR inhibitors. Pro-  
20   hypertensive effects may be direct or indirect but underlying mechanisms are elusive. There are  
21   major gaps in the understanding of how these anti-cancer drugs cause hypertension. In addition,  
22   the relative contributions of direct vascular and renal toxicity to hypertension induced by  
23   alkylating agents, the role of decreased VEGF secretion as a potential mediator of hypertension

1 induced by the Inhibition of mTOR, and the association between aromatase inhibitors and  
2 increased cardiovascular risk including hypertension, need to be elucidated. Whether anti-cancer  
3 therapy-induced hypertension is truly a predictor of drug efficacy awaits further clarification in  
4 large prospective cancer trials. Key gaps also include the timing and frequency of BP monitoring  
5 and cardiovascular risk assessment in patients with cancer during, and after therapy, and the  
6 relationship of concurrent cardiovascular risk factors with anti-cancer therapy-induced  
7 hypertension and outcomes. Evidence-based trials to treat anti-cancer drug-induced hypertension  
8 are lacking and accordingly it remains unclear as to which antihypertensive drugs should be  
9 used.

10

## 11 **FUTURE DIRECTIONS**

12 Future directions for research on hypertension in cancer include epidemiological topics on  
13 common risk factors and mechanisms of hypertension and cancer, optimal strategies for BP  
14 monitoring during and after anti-cancer therapy, and the diagnosis and management of anti-  
15 cancer drug-induced hypertension. Future research will need to address molecular mechanisms  
16 underlying anti-cancer therapy-induced hypertension to better understand measures needed to  
17 minimize cardiovascular toxicity and hypertension, while at the same time optimizing cancer  
18 survival. The bidirectional relationship between cancer and hypertension, pathophysiology of  
19 heart failure with preserved ejection fraction resulting from anti-cancer therapy, risk of lifetime  
20 exposure to Bruton's TKIs for prolonged periods, extent of lifetime risk from cisplatin exposure,  
21 potential cardiovascular protective effect of Janise kinase inhibitors possibly through their ant-  
22 inflammatory effects are all topics for further exploration. The optimal timing and frequency of  
23 BP monitoring in patients with cancer and cancer survivors on drugs that induce hypertension,

1 particularly at initiation of and changes in cancer medication regimen, must be evaluated. The  
2 optimal BP targets in individuals with cancer will also need to be determined, especially since it  
3 is unclear whether the final BP is more important for end organ effects than the magnitude of  
4 initial BP increase from baseline. Use of algorithms for monitoring vital signs, laboratory values,  
5 and ECG's with certain frequency for particular drugs should be incorporated into treatment  
6 plans for patients on anti-cancer therapy. BP management when cancer medication therapies are  
7 stopped (completed or discontinued) will need to be streamlined, especially since there may be  
8 rebound hypotension. RCTs are needed to investigate the "best antihypertensives" for individuals  
9 with cancer treated with various cancer medications to optimize BP and limit end organ damage.  
10 Of major importance sex and racial/ethnic differences, differential therapeutic responses, as well  
11 as disparities regarding management, outcomes, and adherence in patients with hypertension and  
12 cancer, will need to be carefully evaluated.

13

#### 14 **ACKNOWLEDGMENTS**

15 The following support is acknowledged: JBC, National Institutes of Health (NIH) (K23-  
16 HL133843, R01-HL153646, R01-HL157108, U01-HL160277, U01-TR003734, R01-DK123104,  
17 U24-DK060990, R01-AG074989), AHA Bugher Award; SAB, National Center for Advancing  
18 Translational Sciences, NIH (UL1TR001436, KL2TR001438); NNL, British Heart Foundation  
19 Centre (BHF) (RE/18/6/34217); SMH, NIH (K08 DK118120); GYO, University of Alberta  
20 Hospital Foundation, Canadian Institute of Health Research, Heart and Stroke Foundation,  
21 Canada Research Chair; NJB, NIH (HL145293, DK117875); RMT, BHF (RE/18/6/34217,  
22 CH/12/4/297620), Leducq foundation, Phil Gold Chair-McGill University.

23

1 **CONFLICTS**

2 JBC, SMH, DCHvD have no conflicts. RMT provided expert opinion to Novartis. NJB serves on  
3 the Scientific Advisory Board for Alnylam Pharmaceuticals and as a consultant to Pharvaris and  
4 ESTAR Bio. GYO has received support from Sanofi-Genzyme, Takeda and Bristol Myers  
5 Squibb. NNL has received funding from Roche Diagnostics, Astra Zeneca and Boehringer  
6 Ingelheim and speaker's fees/advisory board fees from Roche, Pharmacosmos, Astra Zeneca and  
7 Novartis. SD has served on advisory boards of Novartis and Astra Zeneca and has received  
8 honoraria from Novartis, Pfizer and Astra Zeneca.

9

10

**FIGURE LEGENDS**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12

**Figure 1.**

Putative mechanisms whereby major classes of anti-cancer therapies cause hypertension. VEGF, Vascular endothelial growth factor; VEGFR, VEGF receptor; BTK, Bruton's tyrosine kinase; PI3K, Phosphoinositide 3-kinases; CD47, Cluster of Differentiation 47; MEK, mitogen-activated protein kinase kinase.

**Figure 2.**

Practical suggestions for the diagnosis and management of hypertension before, during and after commencing anti-cancer therapy.



1 **REFERENCES**

- 2 1. Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, Stovall  
3 M, Chow EJ, Sklar CA, Mulrooney DA, Mertens AC, Border W, Durand JB, Robison LL and  
4 Meacham LR. Modifiable risk factors and major cardiac events among adult survivors of  
5 childhood cancer. *J Clin Oncol.* 2013;31:3673-80.
- 6 2. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-Kangevari M,  
7 Abbastabar H, Abd-Allah F, Abdelalim A, Abdollahi M, Abdollahpour I, Abolhassani H,  
8 Aboyans V, Abrams EM, Abreu LG, Abrigo MRM, Abu-Raddad LJ, Abushouk AI, Acebedo A,  
9 Ackerman IN, Adabi M, Adamu AA, Adebayo OM, Adekanmbi V, Adelson JD, Adetokunboh  
10 OO, Adham D, Afshari M, Afshin A, Agardh EE, Agarwal G, Agesa KM, Aghaali M, Aghamir  
11 SMK, Agrawal A, Ahmad T, Ahmadi A, Ahmadi M, Ahmadi H, Ahmadpour E, Akalu TY,  
12 Akinyemi RO, Akinyemiju T, Akombi B, Al-Aly Z, Alam K, Alam N, Alam S, Alam T, Alanzi  
13 TM, Albertson SB, Alcalde-Rabanal JE, Alema NM, Ali M, Ali S, Alicandro G, Alijanzadeh M,  
14 Alinia C, Alipour V, Aljunid SM, Alla F, Allebeck P, Almasi-Hashiani A, Alonso J, Al-Raddadi  
15 RM, Altirkawi KA, Alvis-Guzman N, Alvis-Zakzuk NJ, Amini S, Amini-Rarani M,  
16 Aminorroaya A, Amiri F, Amit AML, Amugsi DA, Amul GGH, Anderlini D, Andrei CL, Andrei  
17 T, Anjomshoa M, Ansari F, Ansari I, Ansari-Moghaddam A, Antonio CAT, Antony CM,  
18 Antriyandarti E, Anvari D, Anwer R, Arabloo J, Arab-Zozani M, Aravkin AY, Ariani F, Ärnlov  
19 J, Aryal KK, Arzani A, Asadi-Aliabadi M, Asadi-Pooya AA, Asghari B, Ashbaugh C, Atnafu  
20 DD, Atre SR, Ausloos F, Ausloos M, Ayala Quintanilla BP, Ayano G, Ayanore MA, Aynalem  
21 YA, Azari S, Azarian G, Azene ZN, Babae E, Badawi A, Bagherzadeh M, Bakhshaei MH,  
22 Bakhtiari A, Balakrishnan S, Balalla S, Balassyano S, Banach M, Banik PC, Bannick MS, Bante  
23 AB, Baraki AG, Barboza MA, Barker-Collo SL, Barthelemy CM, Barua L, Barzegar A, Basu S,

1 Baune BT, Bayati M, Bazmandegan G, Bedi N, Beghi E, Béjot Y, Bello AK, Bender RG,  
 2 Bennett DA, Bennitt FB, Bensenor IM, Benziger CP, Berhe K, Bernabe E, Bertolacci GJ,  
 3 Bhageerathy R, Bhala N, Bhandari D, Bhardwaj P, Bhattacharyya K, Bhutta ZA, Bibi S, Biehl  
 4 MH, Bikbov B, Bin Sayeed MS, Biondi A, Birihane BM, Bisanzio D, Bisignano C, Biswas RK,  
 5 Bohlouli S, Bohluli M, Bolla SRR, Bolor A, Boon-Dooley AS, Borges G, Borzi AM, Bourne R,  
 6 Brady OJ, Brauer M, Brayne C, Breitborde NJK, Brenner H, Briant PS, Briggs AM, Briko NI,  
 7 Britton GB, Bryazka D, Buchbinder R, Bumgarner BR, Busse R, Butt ZA, Caetano dos Santos  
 8 FL, Cámara LLAA, Campos-Nonato IR, Car J, Cárdenas R, Carreras G, Carrero JJ, Carvalho F,  
 9 Castaldelli-Maia JM, Castañeda-Orjuela CA, Castelpietra G, Castle CD, Castro F, Catalá-López  
 10 F, Causey K, Cederroth CR, Cercy KM, Cerin E, Chandan JS, Chang AR, Charlson FJ, Chattu  
 11 VK, Chaturvedi S, Chimed-Ochir O, Chin KL, Cho DY, Christensen H, Chu D-T, Chung MT,  
 12 Cicutini FM, Ciobanu LG, Cirillo M, Collins EL, Compton K, Conti S, Cortesi PA, Costa VM,  
 13 Cousin E, Cowden RG, Cowie BC, Cromwell EA, Cross DH, Crowe CS, Cruz JA, Cunningham  
 14 M, Dahlawi SMA, Damiani G, Dandona L, Dandona R, Darwesh AM, Daryani A, Das JK, Das  
 15 Gupta R, das Neves J, Dávila-Cervantes CA, Davletov K, De Leo D, Dean FE, DeCleene NK,  
 16 Deen A, Degenhardt L, Dellavalle RP, Demeke FM, Demsie DG, Denova-Gutiérrez E, Dereje  
 17 ND, Dervenis N, Desai R, Desalew A, Dessie GA, Dharmaratne SD, Dhungana GP,  
 18 Dianatinasab M, Diaz D, Dibaji Forooshani ZS, Dingels ZV, Dirac MA, Djalalinia S, Do HT,  
 19 Dokova K, Dorostkar F, Doshi CP, Doshmangir L, Douiri A, Doxey MC, Driscoll TR, Dunachie  
 20 SJ, Duncan BB, Duraes AR, Eagan AW, Ebrahimi Kalan M, Edvardsson D, Ehrlich JR, El  
 21 Nahas N, El Sayed I, El Tantawi M, Elbarazi I, Elgendy IY, Elhabashy HR, El-Jaafary SI,  
 22 Elyazar IRF, Emamian MH, Emmons-Bell S, Erskine HE, Eshrati B, Eskandarieh S,  
 23 Esmacilnejad S, Esmacilzadeh F, Esteghamati A, Estep K, Etemadi A, Etisso AE, Farahmand M,

1 Faraj A, Fareed M, Faridnia R, Farinha CSeS, Farioli A, Faro A, Faruque M, Farzadfar F, Fattahi  
2 N, Fazlzadeh M, Feigin VL, Feldman R, Fereshtehnejad S-M, Fernandes E, Ferrari AJ, Ferreira  
3 ML, Filip I, Fischer F, Fisher JL, Fitzgerald R, Flohr C, Flor LS, Foigt NA, Folayan MO, Force  
4 LM, Fornari C, Foroutan M, Fox JT, Freitas M, Fu W, Fukumoto T, Furtado JM, Gad MM,  
5 Gakidou E, Galles NC, Gallus S, Gamkrelidze A, Garcia-Basteiro AL, Gardner WM,  
6 Geberemariam BS, Gebrehiwot AM, Gebremedhin KB, Gebreslassie AAAA, Gershberg  
7 Hayoon A, Gething PW, Ghadimi M, Ghadiri K, Ghafourifard M, Ghajar A, Ghamari F,  
8 Ghashghaee A, Ghiasvand H, Ghith N, Gholamian A, Gilani SA, Gill PS, Gitimoghaddam M,  
9 Giussani G, Goli S, Gomez RS, Gopalani SV, Gorini G, Gorman TM, Gottlich HC, Goudarzi H,  
10 Goulart AC, Goulart BNG, Grada A, Grivna M, Grosso G, Gubari MIM, Gugnani HC,  
11 Guimaraes ALS, Guimarães RA, Guled RA, Guo G, Guo Y, Gupta R, Haagsma JA, Haddock B,  
12 Hafezi-Nejad N, Hafiz A, Hagins H, Haile LM, Hall BJ, Halvaei I, Hamadeh RR, Hamagharib  
13 Abdullah K, Hamilton EB, Han C, Han H, Hankey GJ, Haro JM, Harvey JD, Hasaballah AI,  
14 Hasanzadeh A, Hashemian M, Hassanipour S, Hassankhani H, Havmoeller RJ, Hay RJ, Hay SI,  
15 Hayat K, Heidari B, Heidari G, Heidari-Soureshjani R, Hendrie D, Henrikson HJ, Henry NJ,  
16 Herteliu C, Heydarpour F, Hird TR, Hoek HW, Hole MK, Holla R, Hoogar P, Hosgood HD,  
17 Hosseinzadeh M, Hostiuc M, Hostiuc S, Househ M, Hoy DG, Hsairi M, Hsieh VC-r, Hu G,  
18 Huda TM, Hugo FN, Huynh CK, Hwang B-F, Iannucci VC, Ibitoye SE, Ikuta KS, Ilesanmi OS,  
19 Ilic IM, Ilic MD, Inbaraj LR, Ippolito H, Irvani SSN, Islam MM, Islam M, Islam SMS, Islami F,  
20 Iso H, Ivers RQ, Iwu CCD, Iyamu IO, Jaafari J, Jacobsen KH, Jadidi-Niaragh F, Jafari H,  
21 Jafarinia M, Jahagirdar D, Jahani MA, Jahanmehr N, Jakovljevic M, Jalali A, Jalilian F, James  
22 SL, Janjani H, Janodia MD, Jayatilleke AU, Jeemon P, Jenabi E, Jha RP, Jha V, Ji JS, Jia P, John  
23 O, John-Akinola YO, Johnson CO, Johnson SC, Jonas JB, Joo T, Joshi A, Jozwiak JJ, Jürisson

1 M, Kabir A, Kabir Z, Kalani H, Kalani R, Kalankesh LR, Kalhor R, Kamiab Z, Kanchan T,  
 2 Karami Matin B, Karch A, Karim MA, Karimi SE, Kassa GM, Kassebaum NJ, Katikireddi SV,  
 3 Kawakami N, Kayode GA, Keddie SH, Keller C, Kereselidze M, Khafaie MA, Khalid N, Khan  
 4 M, Khatab K, Khater MM, Khatib MN, Khayamzadeh M, Khodayari MT, Khundkar R,  
 5 Kianipour N, Kieling C, Kim D, Kim Y-E, Kim YJ, Kimokoti RW, Kisa A, Kisa S, Kissimova-  
 6 Skarbek K, Kivimäki M, Kneib CJ, Knudsen AKS, Kocarnik JM, Kolola T, Kopec JA, Kosen S,  
 7 Koul PA, Koyanagi A, Kravchenko MA, Krishan K, Krohn KJ, Kuate Defo B, Kucuk Bicer B,  
 8 Kumar GA, Kumar M, Kumar P, Kumar V, Kumaresh G, Kurmi OP, Kusuma D, Kyu HH, La  
 9 Vecchia C, Lacey B, Lal DK, Lalloo R, Lam JO, Lami FH, Landires I, Lang JJ, Lansingh VC,  
 10 Larson SL, Larsson AO, Lasrado S, Lassi ZS, Lau KM-M, Lavados PM, Lazarus JV, Ledesma  
 11 JR, Lee PH, Lee SWH, LeGrand KE, Leigh J, Leonardi M, Lescinsky H, Leung J, Levi M,  
 12 Lewington S, Li S, Lim L-L, Lin C, Lin R-T, Linehan C, Linn S, Liu H-C, Liu S, Liu Z, Looker  
 13 KJ, Lopez AD, Lopukhov PD, Lorkowski S, Lotufo PA, Lucas TCD, Lugo A, Lunevicius R,  
 14 Lyons RA, Ma J, MacLachlan JH, Maddison ER, Maddison R, Madotto F, Mahasha PW, Mai  
 15 HT, Majeed A, Maled V, Maleki S, Malekzadeh R, Malta DC, Mamun AA, Manafi A, Manafi  
 16 N, Manguerra H, Mansouri B, Mansournia MA, Mantilla Herrera AM, Maravilla JC, Marks A,  
 17 Martins-Melo FR, Martopullo I, Masoumi SZ, Massano J, Massenbourg BB, Mathur MR, Maulik  
 18 PK, McAlinden C, McGrath JJ, McKee M, Mehndiratta MM, Mehri F, Mehta KM, Meitei WB,  
 19 Memiah PTN, Mendoza W, Menezes RG, Mengesha EW, Mengesha MB, Mereke A, Meretoja  
 20 A, Meretoja TJ, Mestrovic T, Miazgowski B, Miazgowski T, Michalek IM, Mihretie KM, Miller  
 21 TR, Mills EJ, Mirica A, Mirrakhimov EM, Mirzaei H, Mirzaei M, Mirzaei-Alavijeh M,  
 22 Misganaw AT, Mithra P, Moazen B, Moghadaszadeh M, Mohamadi E, Mohammad DK,  
 23 Mohammad Y, Mohammad Gholi Mezerji N, Mohammadian-Hafshejani A, Mohammadifard N,

1 Mohammadpourhodki R, Mohammed S, Mokdad AH, Molokhia M, Momen NC, Monasta L,  
2 Mondello S, Mooney MD, Moosazadeh M, Moradi G, Moradi M, Moradi-Lakeh M, Moradzadeh  
3 R, Moraga P, Morales L, Morawska L, Moreno Velásquez I, Morgado-da-Costa J, Morrison SD,  
4 Mosser JF, Mouodi S, Mousavi SM, Mousavi Khaneghah A, Mueller UO, Munro SB, Muriithi  
5 MK, Musa KI, Muthupandian S, Naderi M, Nagarajan AJ, Nagel G, Naghshtabrizi B, Nair S,  
6 Nandi AK, Nangia V, Nansseu JR, Nayak VC, Nazari J, Negoï I, Negoï RI, Netsere HBN,  
7 Ngunjiri JW, Nguyen CT, Nguyen J, Nguyen M, Nguyen M, Nichols E, Nigatu D, Nigatu YT,  
8 Nikbakhsh R, Nixon MR, Nnaji CA, Nomura S, Norrving B, Noubiap JJ, Nowak C, Nunez-  
9 Samudio V, Oțoiu A, Oancea B, Odell CM, Ogbo FA, Oh I-H, Okunga EW, Oladnabi M,  
10 Olagunju AT, Olusanya BO, Olusanya JO, Oluwasanu MM, Omar Bali A, Omer MO, Ong KL,  
11 Onwujekwe OE, Orji AU, Orpana HM, Ortiz A, Ostroff SM, Otstavnov N, Otstavnov SS,  
12 Øverland S, Owolabi MO, P A M, Padubidri JR, Pakhare AP, Palladino R, Pana A, Panda-Jonas  
13 S, Pandey A, Park E-K, Parmar PGK, Pasupula DK, Patel SK, Paternina-Caicedo AJ, Pathak A,  
14 Pathak M, Patten SB, Patton GC, Paudel D, Pazoki Toroudi H, Peden AE, Pennini A, Pepito  
15 VCF, Peprah EK, Pereira A, Pereira DM, Perico N, Pham HQ, Phillips MR, Pigott DM, Pilgrim  
16 T, Pilz TM, Pirsaeheb M, Plana-Ripoll O, Plass D, Pokhrel KN, Polibin RV, Polinder S,  
17 Polkinghorne KR, Postma MJ, Pourjafar H, Pourmalek F, Pourmirza Kalhori R, Pourshams A,  
18 Poznańska A, Prada SI, Prakash V, Pribadi DRA, Pupillo E, Quazi Syed Z, Rabiee M, Rabiee N,  
19 Radfar A, Rafiee A, Rafiei A, Raggi A, Rahimi-Movaghar A, Rahman MA, Rajabpour-Sanati A,  
20 Rajati F, Ramezanzadeh K, Ranabhat CL, Rao PC, Rao SJ, Rasella D, Rastogi P, Rathi P, Rawaf  
21 DL, Rawaf S, Rawal L, Razo C, Redford SB, Reiner RC, Reinig N, Reitsma MB, Remuzzi G,  
22 Renjith V, Renzaho AMN, Resnikoff S, Rezaei N, Rezai Ms, Rezapour A, Rhinehart P-A, Riahi  
23 SM, Ribeiro ALP, Ribeiro DC, Ribeiro D, Rickard J, Roberts NLS, Roberts S, Robinson SR,

1 Roever L, Rolfe S, Ronfani L, Roshandel G, Roth GA, Rubagotti E, Rumisha SF, Sabour S,  
2 Sachdev PS, Saddik B, Sadeghi E, Sadeghi M, Saeidi S, Safi S, Safiri S, Sagar R, Sahebkar A,  
3 Sahraian MA, Sajadi SM, Salahshoor MR, Salamati P, Salehi Zahabi S, Salem H, Salem MRR,  
4 Salimzadeh H, Salomon JA, Salz I, Samad Z, Samy AM, Sanabria J, Santomauro DF, Santos IS,  
5 Santos JV, Santric-Milicevic MM, Saraswathy SYI, Sarmiento-Suárez R, Sarrafzadegan N,  
6 Sartorius B, Sarveazad A, Sathian B, Sathish T, Sattin D, Sbarra AN, Schaeffer LE, Schiavolin  
7 S, Schmidt MI, Schutte AE, Schwebel DC, Schwendicke F, Senbeta AM, Senthilkumaran S,  
8 Sepanlou SG, Shackelford KA, Shadid J, Shahabi S, Shaheen AA, Shaikh MA, Shalash AS,  
9 Shams-Beyranvand M, Shamsizadeh M, Shannawaz M, Sharafi K, Sharara F, Sheena BS,  
10 Sheikhtaheri A, Shetty RS, Shibuya K, Shiferaw WS, Shigematsu M, Shin JI, Shiri R, Shirkoohi  
11 R, Shrimme MG, Shuval K, Siabani S, Sigfusdottir ID, Sigurvinsdottir R, Silva JP, Simpson KE,  
12 Singh A, Singh JA, Skiadaresi E, Skou STS, Skryabin VY, Sobngwi E, Sokhan A, Soltani S,  
13 Sorensen RJD, Soriano JB, Sorrie MB, Soyiri IN, Sreeramareddy CT, Stanaway JD, Stark BA,  
14 Ştefan SC, Stein C, Steiner C, Steiner TJ, Stokes MA, Stovner LJ, Stubbs JL, Sudaryanto A,  
15 Sufiyan MaB, Sulo G, Sultan I, Sykes BL, Sylte DO, Szócska M, Tabarés-Seisdedos R, Tabb  
16 KM, Tadakamadla SK, Taherkhani A, Tajdini M, Takahashi K, Taveira N, Teagle WL, Teame  
17 H, Tehrani-Banihashemi A, Teklehaimanot BF, Terrason S, Tessema ZT, Thankappan KR,  
18 Thomson AM, Tohidinik HR, Tonelli M, Topor-Madry R, Torre AE, Touvier M, Tovani-Palone  
19 MRR, Tran BX, Travillian R, Troeger CE, Truelsen TC, Tsai AC, Tsatsakis A, Tudor Car L,  
20 Tyrovolas S, Uddin R, Ullah S, Undurraga EA, Unnikrishnan B, Vacante M, Vakilian A, Valdez  
21 PR, Varughese S, Vasankari TJ, Vasseghian Y, Venketasubramanian N, Violante FS, Vlassov V,  
22 Vollset SE, Vongpradith A, Vukovic A, Vukovic R, Waheed Y, Walters MK, Wang J, Wang Y,  
23 Wang Y-P, Ward JL, Watson A, Wei J, Weintraub RG, Weiss DJ, Weiss J, Westerman R,

- 1 Whisnant JL, Whiteford HA, Wiangkham T, Wiens KE, Wijeratne T, Wilner LB, Wilson S,  
 2 Wojtyniak B, Wolfe CDA, Wool EE, Wu A-M, Wulf Hanson S, Wunrow HY, Xu G, Xu R,  
 3 Yadgir S, Yahyazadeh Jabbari SH, Yamagishi K, Yaminfirooz M, Yano Y, Yaya S, Yazdi-  
 4 Feyzabadi V, Yearwood JA, Yeheyis TY, Yeshitila YG, Yip P, Yonemoto N, Yoon S-J, Yoosefi  
 5 Lebni J, Younis MZ, Younker TP, Yousefi Z, Yousefifard M, Yousefinezhadi T, Yousuf AY, Yu  
 6 C, Yusefzadeh H, Zahirian Moghadam T, Zaki L, Zaman SB, Zamani M, Zamanian M, Zandian  
 7 H, Zangeneh A, Zastrozhin MS, Zewdie KA, Zhang Y, Zhang Z-J, Zhao JT, Zhao Y, Zheng P,  
 8 Zhou M, Ziapour A, Zimsen SRM, Naghavi M and Murray CJL. Global burden of 369 diseases  
 9 and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global  
 10 Burden of Disease Study 2019. *The Lancet*. 2020;396:1204-1222.
- 11 3. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, Gregg EW,  
 12 Bennett JE, Solomon B, Singleton RK, Sophiea MK, Iurilli MLC, Lhoste VPF, Cowan MJ,  
 13 Savin S, Woodward M, Balanova Y, Cifkova R, Damasceno A, Elliott P, Farzadfar F, He J,  
 14 Ikeda N, Kengne AP, Khang Y-H, Kim HC, Laxmaiah A, Lin H-H, Margozzini Maira P,  
 15 Miranda JJ, Neuhauser H, Sundström J, Varghese C, Widyahening IS, Zdrojewski T, Abarca-  
 16 Gómez L, Abdeen ZA, Abdul Rahim HF, Abu-Rmeileh NM, Acosta-Cazares B, Adams RJ,  
 17 Aekplakorn W, Afsana K, Afzal S, Agdeppa IA, Aghazadeh-Attari J, Aguilar-Salinas CA,  
 18 Agyemang C, Ahmad NA, Ahmadi A, Ahmadi N, Ahmadi N, Ahmadizar F, Ahmed SH, Ahrens  
 19 W, Ajlouni K, Al-Raddadi R, Alarouj M, AlBuhairan F, AlDhukair S, Ali MM, Alkandari A,  
 20 Alkerwi Aa, Allin K, Aly E, Amarapurkar DN, Amougou N, Amouyel P, Andersen LB,  
 21 Anderssen SA, Anjana RM, Ansari-Moghaddam A, Ansong D, Aounallah-Skhiri H, Araújo J,  
 22 Ariansen I, Aris T, Arku RE, Arlappa N, Aryal KK, Aspelund T, Assah FK, Assunção MCF,  
 23 Auvinen J, Avdićová M, Azevedo A, Azimi-Nezhad M, Azizi F, Azmin M, Babu BV, Bahijri S,

1 Balakrishna N, Bamoshmoosh M, Banach M, Banadinović M, Bandosz P, Banegas JR, Baran J,  
 2 Barbagallo CM, Barceló A, Barkat A, Barreto M, Barros AJD, Barros MVG, Bartosiewicz A,  
 3 Basit A, Bastos JLD, Bata I, Batiha AM, Batyrbek A, Baur LA, Beaglehole R, Belavendra A,  
 4 Ben Romdhane H, Benet M, Benson LS, Berkinbayev S, Bernabe-Ortiz A, Bernotiene G, Bettiol  
 5 H, Bezerra J, Bhagyalaxmi A, Bhargava SK, Bia D, Biasch K, Bika Lele EC, Bikbov MM, Bista  
 6 B, Bjerregaard P, Bjertness E, Bjertness MB, Björkelund C, Bloch KV, Blokstra A, Bo S, Bobak  
 7 M, Boeing H, Boggia JG, Boissonnet CP, Bojesen SE, Bongard V, Bonilla-Vargas A, Bopp M,  
 8 Borghs H, Bovet P, Boyer CB, Braeckman L, Brajkovich I, Branca F, Breckenkamp J, Brenner  
 9 H, Brewster LM, Briceño Y, Brito M, Bruno G, Bueno-de-Mesquita HB, Bueno G, Bugge A,  
 10 Burns C, Bursztyrn M, Cabrera de León A, Cacciottolo J, Cameron C, Can G, Cândido APC,  
 11 Capanzana MV, Čapková N, Capuano E, Capuano V, Cardoso VC, Carlsson AC, Carvalho J,  
 12 Casanueva FF, Censi L, Cervantes-Loaiza M, Chadji Georgiou CA, Chamukuttan S, Chan AW,  
 13 Chan Q, Chaturvedi HK, Chaturvedi N, Chee ML, Chen C-J, Chen F, Chen H, Chen S, Chen Z,  
 14 Cheng C-Y, Cheraghian B, Cherkaoui Dekkaki I, Chetrit A, Chien K-L, Chiolero A, Chiou S-T,  
 15 Chirita-Emandi A, Chirlaque M-D, Cho B, Christensen K, Christofaro DG, Chudek J, Cinteza E,  
 16 Claessens F, Clarke J, Clays E, Cohen E, Concin H, Cooper C, Coppinger TC, Costanzo S,  
 17 Cotel D, Cowell C, Craig CL, Crampin AC, Crujeiras AB, Cruz JJ, Csilla S, Cui L, Cureau FV,  
 18 Cuschieri S, D'Arrigo G, d'Orsi E, Dallongeville J, Dankner R, Dantoft TM, Dauchet L,  
 19 Davletov K, De Backer G, De Bacquer D, De Curtis A, de Gaetano G, De Henauw S, de Oliveira  
 20 PD, De Ridder D, De Smedt D, Deepa M, Deev AD, DeGennaro V, Jr., Delisle H, Demarest S,  
 21 Dennison E, Deschamps V, Dhimal M, Di Castelnuovo AF, Dias-da-Costa JS, Diaz A,  
 22 Dickerson TT, Dika Z, Djalalinia S, Do HTP, Dobson AJ, Donfrancesco C, Donoso SP, Döring  
 23 A, Dorobantu M, Dörr M, Doua K, Dragano N, Drygas W, Duante CA, Duboz P, Duda RB,



1 Dulskiene V, Dushpanova A, Džakula A, Dzerve V, Dzionkowska-Zaborszczyk E, Eddie R,  
 2 Eftekhar E, Eggertsen R, Eghtesad S, Eiben G, Ekelund U, El-Khateeb M, El Ati J, Eldemire-  
 3 Shearer D, Eliassen M, Elosua R, Erasmus RT, Erbel R, Erem C, Eriksen L, Eriksson JG,  
 4 Escobedo-de la Peña J, Eslami S, Esmacili A, Evans A, Faeh D, Fakhretdinova AA, Fall CH,  
 5 Faramarzi E, Farjam M, Fattahi MR, Fawwad A, Felix-Redondo FJ, Felix SB, Ferguson TS,  
 6 Fernandes RA, Fernández-Bergés D, Ferrante D, Ferrao T, Ferrari M, Ferrario MM, Ferreccio C,  
 7 Ferreira HS, Ferrer E, Ferrieres J, Figueiró TH, Fink G, Fischer K, Foo LH, Forsner M, Fouad  
 8 HM, Francis DK, Franco MdC, Frikke-Schmidt R, Frontera G, Fuchs FD, Fuchs SC, Fujita Y,  
 9 Fumihiko M, Furdela V, Furer A, Furusawa T, Gaciong Z, Galbarczyk A, Galenkamp H,  
 10 Galvano F, Gao J, Gao P, Garcia-de-la-Hera M, Garcia P, Garetta D, Garnett SP, Gaspoz J-M,  
 11 Gasull M, Gazzinelli A, Gehring U, Geleijnse JM, George R, Ghanbari A, Ghasemi E,  
 12 Gheorghe-Fronea O-F, Ghimire A, Gialluisi A, Giampaoli S, Gieger C, Gill TK, Giovannelli J,  
 13 Gironella G, Giwerzman A, Gkiouras K, Goldberg M, Goldsmith RA, Gomez LF, Gomula A,  
 14 Gonçalves H, Gonçalves M, Gonçalves Cordeiro da Silva B, Gonzalez-Chica DA, Gonzalez-  
 15 Gross M, González-Rivas JP, González-Villalpando C, González-Villalpando M-E, Gonzalez  
 16 AR, Gorbea MB, Gottrand F, Graff-Iversen S, Grafnetter D, Grajda A, Grammatikopoulou MG,  
 17 Gregor RD, Grodzicki T, Grosso G, Gruden G, Gu D, Guan OP, Gudmundsson EF, Gudnason V,  
 18 Guerrero R, Guessous I, Guimaraes AL, Gulliford MC, Gunnlaugsdottir J, Gunter MJ, Gupta PC,  
 19 Gupta R, Gureje O, Gurzkowska B, Gutierrez L, Gutzwiller F, Ha S, Hadaegh F, Haghshenas R,  
 20 Hakimi H, Halkjær J, Hambleton IR, Hamzeh B, Hange D, Hanif AAM, Hantunen S, Hao J,  
 21 Hardman CM, Hari Kumar R, Hashemi-Shahri SM, Hata J, Haugsgjerd T, Hayes AJ, He Y,  
 22 Heier M, Hendriks ME, Henrique RdS, Henriques A, Hernandez Cadena L, Herqutanto, Herrala  
 23 S, Heshmat R, Hill AG, Ho SY, Ho SC, Hobbs M, Holdsworth M, Homayounfar R, Horasan

1 Dinc G, Horimoto ARVR, Hormiga CM, Horta BL, Houti L, Howitt C, Htay TT, Htet AS, Htike  
2 MMT, Hu Y, Huerta JM, Huhtaniemi IT, Huiart L, Huisman M, Hussein AS, Huybrechts I,  
3 Hwalla N, Iacoviello L, Iannone AG, Ibrahim MM, Ibrahim Wong N, Ikram MA, Iotova V,  
4 Irazola VE, Ishida T, Isiguzo GC, Islam M, Islam SMS, Iwasaki M, Jackson RT, Jacobs JM,  
5 Jaddou HY, Jafar T, James K, Jamrozik K, Janszky I, Janus E, Jarvelin M-R, Jasienska G,  
6 Jelaković A, Jelaković B, Jennings G, Jha AK, Jiang CQ, Jimenez RO, Jöckel K-H, Joffres M,  
7 Johansson M, Jokelainen JJ, Jonas JB, Jørgensen T, Joshi P, Joukar F, Józwiak J, Juolevi A,  
8 Jurak G, Jureša V, Kaaks R, Kafatos A, Kajantie EO, Kalamatayeva Z, Kalpourtzi N, Kalter-  
9 Leibovici O, Kampmann FB, Kannan S, Karaglani E, Kårhus LL, Karki KB, Katibeh M, Katz J,  
10 Kauhanen J, Kaur P, Kavousi M, Kazakbaeva GM, Keil U, Keinan Boker L, Keinänen-  
11 Kiukaanniemi S, Kelishadi R, Kemper HCG, Keramati M, Kerimkulova A, Kersting M, Key T,  
12 Khader YS, Khalili D, Khaw K-T, Kheiri B, Kheradmand M, Khosravi A, Kiechl-Kohlendorfer  
13 U, Kiechl S, Killewo J, Kim DW, Kim J, Klakk H, Klimek M, Klumbiene J, Knoflach M, Kolle  
14 E, Kolsteren P, Kontto JP, Korpelainen R, Korrovits P, Kos J, Koskinen S, Kouda K, Kowlessur  
15 S, Koziel S, Kratenova J, Kriaucioniene V, Kristensen PL, Krokstad S, Kromhout D, Kruger HS,  
16 Kubinova R, Kuciene R, Kujala UM, Kulaga Z, Kumar RK, Kurjata P, Kusuma YS, Kutsenko  
17 V, Kuulasmaa K, Kyobutungi C, Laatikainen T, Lachat C, Laid Y, Lam TH, Landrove O,  
18 Lanska V, Lappas G, Larijani B, Latt TS, Le Coroller G, Le Nguyen Bao K, Le TD, Lee J, Lee J,  
19 Lehmann N, Lehtimäki T, Lemogoum D, Levitt NS, Li Y, Lilly CL, Lim W-Y, Lima-Costa MF,  
20 Lin X, Lin Y-T, Lind L, Lingam V, Linneberg A, Lissner L, Litwin M, Lo W-C, Loit H-M,  
21 Lopez-Garcia E, Lopez T, Lotufo PA, Lozano JE, Lukačević Lovrenčić I, Lukrafka JL, Luksiene  
22 D, Lundqvist A, Lundqvist R, Lunet N, Lustigová M, Luszczki E, Ma G, Ma J, Machado-Coelho  
23 GLL, Machado-Rodrigues AM, Macia E, Macieira LM, Madar AA, Maggi S, Magliano DJ,

1 Magriplis E, Mahasampath G, Maire B, Majer M, Makdisse M, Malekzadeh F, Malekzadeh R,  
2 Malhotra R, Mallikharjuna Rao K, Malyutina SK, Maniego LV, Manios Y, Mann JI, Mansour-  
3 Ghanaei F, Manzato E, Marcil A, Mårild SB, Marinović Glavić M, Marques-Vidal P, Marques  
4 LP, Marrugat J, Martorell R, Mascarenhas LP, Matasin M, Mathiesen EB, Mathur P,  
5 Matijasevich A, Matlosz P, Matsha TE, Mavrogianni C, Mbanya JCN, Mc Donald Posso AJ,  
6 McFarlane SR, McGarvey ST, McLachlan S, McLean RM, McLean SB, McNulty BA, Mediene  
7 Benchekor S, Medzioniene J, Mehdipour P, Mehlig K, Mehrparvar AH, Meirhaeghe A,  
8 Meisinger C, Mendoza Montano C, Menezes AMB, Menon GR, Mereke A, Meshram II,  
9 Metspalu A, Meyer HE, Mi J, Michels N, Mikkil K, Milkowska K, Miller JC, Minderico CS,  
10 Mini GK, Mirjalili MR, Mirrakhimov E, Mišigoj-Duraković M, Modesti PA, Moghaddam SS,  
11 Mohajer B, Mohamed MK, Mohamed SF, Mohammad K, Mohammadi MR, Mohammadi Z,  
12 Mohammadifard N, Mohammadpourhodki R, Mohan V, Mohanna S, Mohd Yusoff MF,  
13 Mohebbi I, Mohebi F, Moitry M, Møllehave LT, Molnár D, Momenan A, Mondo CK,  
14 Monterrubio-Flores E, Monyeki KDK, Moon JS, Moosazadeh M, Moreira LB, Morejon A,  
15 Moreno LA, Morgan K, Moschonis G, Mossakowska M, Mostafa A, Mostafavi S-A, Mota J,  
16 Motlagh ME, Motta J, Moura-dos-Santos MA, Mridha MK, Msyamboza KP, Mu TT, Muhihi  
17 AJ, Muiesan ML, Müller-Nurasyid M, Murphy N, Mursu J, Musa KI, Musić Milanović S, Musil  
18 V, Mustafa N, Nabipour I, Naderimagham S, Nagel G, Naidu BM, Najafi F, Nakamura H,  
19 Námešná J, Nang EEK, Nangia VB, Narake S, Ndiaye NC, Neal WA, Nejatizadeh A, Nenko I,  
20 Neovius M, Nguyen CT, Nguyen ND, Nguyen QV, Nguyen QN, Nieto-Martínez RE, Niiranen  
21 TJ, Nikitin YP, Ninomiya T, Nishtar S, Njelekela MA, Noale M, Noboa OA, Noorbala AA,  
22 Norat T, Nordendahl M, Nordestgaard BG, Noto D, Nowak-Szczepanska N, Nsour MA, Nunes  
23 B, O'Neill TW, O'Reilly D, Ochimana C, Oda E, Odili AN, Oh K, Ohara K, Ohtsuka R, Olié V,

1 Olinto MTA, Oliveira IO, Omar MA, Onat A, Ong SK, Ono LM, Ordunez P, Ornelas R, Ortiz  
2 PJ, Osmond C, Ostojic SM, Ostovar A, Otero JA, Overvad K, Owusu-Dabo E, Paccaud FM,  
3 Padez C, Pahomova E, Paiva KMD, Pająk A, Palli D, Palmieri L, Pan W-H, Panda-Jonas S,  
4 Panza F, Paoli M, Papandreou D, Park S-W, Park S, Parnell WR, Parsaeian M, Pasquet P, Patel  
5 ND, Pavlyshyn H, Pećin I, Pednekar MS, Pedro JM, Peer N, Peixoto SV, Peltonen M, Pereira  
6 AC, Peres KGDA, Peres MA, Peters A, Petkeviciene J, Peykari N, Pham ST, Pichardo RN,  
7 Pigeot I, Pikhart H, Pilav A, Pilotto L, Pitakaka F, Piwonska A, Pizarro An, Plans-Rubió P,  
8 Polašek O, Porta M, Poudyal A, Pourfarzi F, Pourshams A, Poustchi H, Pradeepa R, Price AJ,  
9 Price JF, Providencia R, Puhakka SE, Puiu M, Punab M, Qasrawi RF, Qorbani M, Queiroz D,  
10 Quoc Bao T, Radić I, Radisauskas R, Rahimikazerooni S, Rahman M, Raitakari O, Raj M,  
11 Rakhimova EM, Ramachandra Rao S, Ramachandran A, Ramos E, Rampal L, Rampal S, Rangel  
12 Reina DA, Rarra V, Rech CR, Redon J, Reganit PFM, Regecová V, Revilla L, Rezaianzadeh A,  
13 Ribeiro R, Riboli E, Richter A, Rigo F, Rinke de Wit TF, Ritti-Dias RM, Robitaille C,  
14 Rodríguez-Artalejo F, Rodríguez-Perez MdC, Rodríguez-Villamizar LA, Roggenbuck U, Rojas-  
15 Martinez R, Romaguera D, Romeo EL, Rosengren A, Roy JGR, Rubinstein A, Ruidavets J-B,  
16 Ruiz-Betancourt BS, Ruiz-Castell M, Rusakova IA, Russo P, Rutkowski M, Sabanayagam C,  
17 Sabbaghi H, Sachdev HS, Sadjadi A, Safarpour AR, Safi S, Safiri S, Saidi O, Sakarya S, Saki N,  
18 Salanave B, Salazar Martinez E, Salmerón D, Salomaa V, Salonen JT, Salvetti M, Sánchez-  
19 Abanto J, Sans S, Santos DA, Santos IS, Santos LC, Santos MP, Santos R, Saramies JL,  
20 Sardinha LB, Sarganas G, Sarrafzadegan N, Sathish T, Saum K-U, Savva S, Sawada N, Sbaraini  
21 M, Scazufca M, Schaan BD, Schargrodsky H, Schipf S, Schmidt CO, Schnohr P, Schöttker B,  
22 Schramm S, Schultz C, Schutte AE, Sebert S, Sein AA, Sen A, Senbanjo IO, Sepanlou SG,  
23 Servais J, Shalnova SA, Shamah-Levy T, Shamshirgaran M, Shanthirani CS, Sharafkhan M,

1 Sharma SK, Shaw JE, Shayanrad A, Shayesteh AA, Shi Z, Shibuya K, Shimizu-Furusawa H,  
 2 Shin DW, Shirani M, Shiri R, Shrestha N, Si-Ramlee K, Siani A, Siantar R, Sibai AM, Silva  
 3 CRdM, Silva DAS, Simon M, Simons J, Simons LA, Sjöström M, Slowikowska-Hilczer J,  
 4 Slusarczyk P, Smeeth L, So H-K, Soares FC, Sobngwi E, Söderberg S, Soemantri A, Sofat R,  
 5 Solfrizzi V, Somi MH, Sonestedt E, Song Y, Sørensen TIA, Sørgerd EP, Sorić M, Sossa Jérôme  
 6 C, Soumaré A, Sparboe-Nilsen B, Sparrenberger K, Staessen JA, Starc G, Stavreski B, Steene-  
 7 Johannessen J, Stehle P, Stein AD, Stergiou GS, Stessman J, Stieber J, Stöckl D, Stocks T,  
 8 Stokwiszewski J, Stronks K, Strufaldi MW, Suka M, Sun C-A, Sung Y-T, Suriyawongpaisal P,  
 9 Sy RG, Syddall HE, Sylva RC, Szklo M, Tai ES, Tammesoo M-L, Tamosiunas A, Tan EJ, Tang  
 10 X, Tanser F, Tao Y, Tarawneh MR, Tarqui-Mamani CB, Taylor A, Taylor J, Tebar WR, Tell  
 11 GS, Tello T, Tham YC, Thankappan KR, Theobald H, Theodoridis X, Thijs L, Thinggaard M,  
 12 Thomas N, Thorand B, Thuesen BH, Timmermans EJ, Tjandrarini DH, Tjonneland A, Toft U,  
 13 Tolonen HK, Tolstrup JS, Topbas M, Topór-Madry R, Tormo MJ, Tornaritis MJ, Torrent M,  
 14 Torres-Collado L, Touloumi G, Traissac P, Triantafyllou A, Trichopoulos D, Trichopoulou A,  
 15 Trinh OTH, Trivedi A, Tshepo L, Tsugane S, Tuliakova AM, Tulloch-Reid MK, Tullu F,  
 16 Tuomainen T-P, Tuomilehto J, Turley ML, Twig G, Tynelius P, Tzourio C, Ueda P, Ugel E,  
 17 Ulmer H, Uusitalo HMT, Valdivia G, Valvi D, van Dam RM, van den Born B-J, Van der  
 18 Heyden J, van der Schouw YT, Van Herck K, Van Minh H, Van Schoor NM, van Valkengoed  
 19 IGM, van Zutphen EM, Vanderschueren D, Vanuzzo D, Varbo A, Vasan SK, Vega T,  
 20 Veidebaum T, Velasquez-Melendez G, Veronesi G, Verschuren WMM, Verstraeten R, Victora  
 21 CG, Viet L, Villalpando S, Vineis P, Vioque J, Virtanen JK, Visvikis-Siest S, Viswanathan B,  
 22 Vlasoff T, Vollenweider P, Voutilainen A, Wade AN, Walton J, Wambiya EOA, Wan Bebakar  
 23 WM, Wan Mohamud WN, Wanderley Júnior RdS, Wang M-D, Wang N, Wang Q, Wang X,

- 1 Wang YX, Wang Y-W, Wannamethee SG, Wareham N, Wei W, Weres A, Werner B, Whincup  
 2 PH, Widhalm K, Wiecek A, Wilks RJ, Willeit J, Willeit P, Williams EA, Wilsgaard T,  
 3 Wojtyniak B, Wong-McClure RA, Wong A, Wong TY, Woo J, Wu FC, Wu S, Wyszynska J, Xu  
 4 H, Xu L, Yaacob NA, Yan W, Yang L, Yang X, Yang Y, Yasuharu T, Ye X, Yiallourous PK,  
 5 Yoosefi M, Yoshihara A, You S-L, Younger-Coleman NO, Yusoff AF, Zainuddin AA, Zakavi  
 6 SR, Zamani F, Zambon S, Zampelas A, Zapata ME, Zaw KK, Zejglicova K, Zeljkovic Vrkic T,  
 7 Zeng Y, Zhang L, Zhang Z-Y, Zhao D, Zhao M-H, Zhen S, Zheng Y, Zholdin B, Zhu D, Zins M,  
 8 Zitt E, Zocalo Y, Zoghiami N, Zuñiga Cisneros J and Ezzati M. Worldwide trends in  
 9 hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled  
 10 analysis of 1201 population-representative studies with 104 million participants. *The Lancet*.  
 11 2021;398:957-980.
- 12 4. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb  
 13 C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele  
 14 B, Smith SC, Jr., Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Sr., Williamson  
 15 JD and Wright JT, Jr. 2017  
 16 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the  
 17 Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report  
 18 of the American College of Cardiology/American Heart Association Task Force on Clinical  
 19 Practice Guidelines. *Hypertension*. 2018;71:e13-e115.
- 20 5. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F.  
 21 Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide  
 22 for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021;71:209-249.

- 1 6. Seretis A, Cividini S, Markozannes G, Tseretopoulou X, Lopez DS, Ntzani EE and  
2 Tsilidis KK. Association between blood pressure and risk of cancer development: a systematic  
3 review and meta-analysis of observational studies. *Sci Rep.* 2019;9:8565.
- 4 7. Piccirillo JF, Tierney RM, Costas I, Grove L and Spitznagel EL, Jr. Prognostic  
5 importance of comorbidity in a hospital-based cancer registry. *JAMA.* 2004;291:2441-7.
- 6 8. van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J,  
7 Mathijssen RHJ, Danser AHJ and Lang NN. Hypertension and Prohypertensive Antineoplastic  
8 Therapies in Cancer Patients. *Circ Res.* 2021;128:1040-1061.
- 9 9. Koene RJ, Prizment AE, Blaes A and Konety SH. Shared Risk Factors in Cardiovascular  
10 Disease and Cancer. *Circulation.* 2016;133:1104-14.
- 11 10. Cohen JB, Geara AS, Hogan JJ and Townsend RR. Hypertension in Cancer Patients and  
12 Survivors: Epidemiology, Diagnosis, and Management. *JACC CardioOncol.* 2019;1:238-251.
- 13 11. Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, Kelly SP and  
14 Zaorsky NG. A population-based study of cardiovascular disease mortality risk in US cancer  
15 patients. *Eur Heart J.* 2019;40:3889-3897.
- 16 12. Camarda N, Travers R, Yang VK, London C and Jaffe IZ. VEGF Receptor Inhibitor-  
17 Induced Hypertension: Emerging Mechanisms and Clinical Implications. *Curr Oncol Rep.*  
18 2022;24:463-474.
- 19 13. Totzeck M, Mincu RI, Mrotzek S, Schadendorf D and Rassaf T. Cardiovascular diseases  
20 in patients receiving small molecules with anti-vascular endothelial growth factor activity: A  
21 meta-analysis of approximately 29,000 cancer patients. *Eur J Prev Cardiol.* 2018;25:482-494.
- 22 14. Osumi H, Shinozaki E, Ooki A, Wakatsuki T, Kamiimabeppu D, Sato T, Nakayama I,  
23 Ogura M, Takahari D, Chin K and Yamaguchi K. Early hypertension and neutropenia are

- 1 predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI  
2 and vascular endothelial growth factor inhibitors as second-line chemotherapy. *Cancer Med.*  
3 2021;10:615-625.
- 4 15. Neves KB, Rios FJ, van der Mey L, Alves-Lopes R, Cameron AC, Volpe M, Montezano  
5 AC, Savoia C and Touyz RM. VEGFR (Vascular Endothelial Growth Factor Receptor)  
6 Inhibition Induces Cardiovascular Damage via Redox-Sensitive Processes. *Hypertension.*  
7 2018;71:638-647.
- 8 16. van der Veldt AA, de Boer MP, Boven E, Eringa EC, van den Eertwegh AJ, van  
9 Hinsbergh VW, Smulders YM and Serne EH. Reduction in skin microvascular density and  
10 changes in vessel morphology in patients treated with sunitinib. *Anticancer Drugs.* 2010;21:439-  
11 46.
- 12 17. Mincu RI, Mahabadi AA, Michel L, Mrotzek SM, Schadendorf D, Rassaf T and Totzeck  
13 M. Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic  
14 Review and Meta-analysis. *JAMA Netw Open.* 2019;2:e198890.
- 15 18. Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, Guha A, Rogers KA,  
16 Bhat S, Byrd JC, Woyach JA, Awan F and Addison D. Hypertension and incident cardiovascular  
17 events following ibrutinib initiation. *Blood.* 2019;134:1919-1928.
- 18 19. Caldeira D, Alves D, Costa J, Ferreira JJ and Pinto FJ. Ibrutinib increases the risk of  
19 hypertension and atrial fibrillation: Systematic review and meta-analysis. *PLoS One.*  
20 2019;14:e0211228.
- 21 20. Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M,  
22 Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O,  
23 Weiss J, de la Fouchardiere C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J,



- 1 Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich  
2 D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH and  
3 Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. *The New England*  
4 *journal of medicine*. 2020;383:825-835.
- 5 21. Gainor JF, Curigliano G, Kim D-W, Lee DH, Besse B, Baik CS, Doebele RC, Cassier  
6 PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV,  
7 Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD and  
8 Subbiah V. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-  
9 cohort, open-label, phase 1/2 study. *The Lancet Oncology*. 2021;22:959-969.
- 10 22. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M,  
11 Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD,  
12 Berek JS, Dorum A, Tinker AV, du Bois A, Gonzalez-Martin A, Follana P, Benigno B,  
13 Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balsler JP, Agarwal S, Matulonis UA and  
14 Investigators E-ON. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian  
15 Cancer. *The New England journal of medicine*. 2016;375:2154-2164.
- 16 23. Wu XH, Zhu JQ, Yin RT, Yang JX, Liu JH, Wang J, Wu LY, Liu ZL, Gao YN, Wang  
17 DB, Lou G, Yang HY, Zhou Q, Kong BH, Huang Y, Chen LP, Li GL, An RF, Wang K, Zhang  
18 Y, Yan XJ, Lu X, Lu WG, Hao M, Wang L, Cui H, Chen QH, Abulizi G, Huang XH, Tian XF,  
19 Wen H, Zhang C, Hou JM and Mirza MR. Niraparib maintenance therapy in patients with  
20 platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a  
21 randomized, double-blind, placebo-controlled phase III trial(). *Ann Oncol*. 2021;32:512-521.
- 22 24. Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, Pierre V, Charlab  
23 R, Ramamoorthy A, Song P, Li F, Yu J, Manheng W, Palmby TR, Ghosh S, Horne HN, Lee EY,


- 1 Philip R, Dave K, Chen XH, Kelly SL, Janoria KG, Banerjee A, Eradiri O, Dinin J, Goldberg  
2 KB, Pierce WF, Ibrahim A, Kluetz PG, Blumenthal GM, Beaver JA and Pazdur R. FDA  
3 Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent  
4 Ovarian Cancer in Response to Platinum-Based Chemotherapy. *Clin Cancer Res.* 2018;24:4066-  
5 4071.
- 6 25. Kubiczkova L, Pour L, Sedlarikova L, Hajek R and Sevcikova S. Proteasome inhibitors -  
7 molecular basis and current perspectives in multiple myeloma. *J Cell Mol Med.* 2014;18:947-61.
- 8 26. Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng W-J, Oriol A, Orłowski  
9 RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A,  
10 Kimball AS and Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple  
11 myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised,  
12 phase 3 trial. *The Lancet Oncology.* 2017;18:1327-1337.
- 13 27. Bruno G, Bringhen S, Maffei I, Iannaccone A, Crea T, Ravera A, Astarita A, Vallelonga  
14 F, Salvini M, Gay F, Veglio F and Milan A. Cardiovascular Organ Damage and Blood Pressure  
15 Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy.  
16 *Cancers (Basel).* 2019;11.
- 17 28. Wei Q and Xia Y. Proteasome inhibition down-regulates endothelial nitric-oxide  
18 synthase phosphorylation and function. *J Biol Chem.* 2006;281:21652-21659.
- 19 29. Gavazzoni M, Vizzardi E, Gorga E, Bonadei I, Rossi L, Belotti A, Rossi G, Ribolla R,  
20 Metra M and Raddino R. Mechanism of cardiovascular toxicity by proteasome inhibitors: New  
21 paradigm derived from clinical and pre-clinical evidence. *Eur J Pharmacol.* 2018;828:80-88.


- 1 30. Sagstuen H, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, Wilsgaard T and Bremnes  
2 RM. Blood pressure and body mass index in long-term survivors of testicular cancer. *J Clin*  
3 *Oncol.* 2005;23:4980-90.
- 4 31. Boer H, Proost JH, Nuver J, Bunskoek S, Gietema JQ, Geubels BM, Altena R, Zwart N,  
5 Oosting SF, Vonk JM, Lefrandt JD, Uges DR, Meijer C, de Vries EG and Gietema JA. Long-  
6 term exposure to circulating platinum is associated with late effects of treatment in testicular  
7 cancer survivors. *Ann Oncol.* 2015;26:2305-10.
- 8 32. dos Santos NA, Carvalho Rodrigues MA, Martins NM and dos Santos AC. Cisplatin-  
9 induced nephrotoxicity and targets of nephroprotection: an update. *Arch Toxicol.* 2012;86:1233-  
10 50.
- 11 33. Choi YM, Kim HK, Shim W, Anwar MA, Kwon JW, Kwon HK, Kim HJ, Jeong H, Kim  
12 HM, Hwang D, Kim HS and Choi S. Mechanism of Cisplatin-Induced Cytotoxicity Is Correlated  
13 to Impaired Metabolism Due to Mitochondrial ROS Generation. *PLoS One.* 2015;10:e0135083.
- 14 34. Knijnenburg SL, Jaspers MW, van der Pal HJ, Schouten-van Meeteren AY, Bouts AH,  
15 Lieverst JA, Bokenkamp A, Koning CC, Oldenburger F, Wilde JC, van Leeuwen FE, Caron HN  
16 and Kremer LC. Renal dysfunction and elevated blood pressure in long-term childhood cancer  
17 survivors. *Clin J Am Soc Nephrol.* 2012;7:1416-27.
- 18 35. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson  
19 C, Orlando L, Cinieri S, de BF, Viale G and Goldhirsch A. Low-dose oral methotrexate and  
20 cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular  
21 endothelial growth factor levels. *Ann Oncol.* 2002;13:73-80.

- 1 36. Kooijmans EC, Bokenkamp A, Tjahjadi NS, Tettero JM, van Dulmen-den Broeder E, van  
2 der Pal HJ and Veening MA. Early and late adverse renal effects after potentially nephrotoxic  
3 treatment for childhood cancer. *Cochrane Database Syst Rev.* 2019;3:CD008944.
- 4 37. Hamilton BK, Rybicki L, Dean R, Majhail NS, Haddad H, Abounader D, Hanna R,  
5 Sobecks R, Duong H, Hill BT, Copelan E, Bolwell B and Kalaycio M. Cyclosporine in  
6 combination with mycophenolate mofetil versus methotrexate for graft versus host disease  
7 prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell  
8 transplantation. *Am J Hematol.* 2015;90:144-8.
- 9 38. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A  
10 and Bohlius J. Erythropoietin or darbepoetin for patients with cancer. *Cochrane Database Syst*  
11 *Rev.* 2012;12:CD003407.
- 12 39. Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, Raymer  
13 JM, Romero JC, Wiesner RH, Krom RAF and Burnett JC. Cyclosporine-Induced Hypertension  
14 After Transplantation. *Mayo Clinic Proceedings.* 1994;69:1182-1193.
- 15 40. Hoskova L, Malek I, Kopkan L and Kautzner J. Pathophysiological mechanisms of  
16 calcineurin inhibitor-induced nephrotoxicity and arterial hypertension. *Physiol Res.* 2017;66:167-  
17 180.
- 18 41. Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnieriek  
19 J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim H-J, Wood K, Dutcus C and  
20 Larkin J. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell  
21 carcinoma: a randomised, phase 2, open-label, multicentre trial. *The Lancet Oncology.*  
22 2015;16:1473-1482.

- 1 42. Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, Muraglia A,  
2 Porcaro AB, Siracusano S, Brunelli M, Mazzarotto R, Artibani W and Tortora G. The  
3 Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. *Clin Genitourin*  
4 *Cancer*. 2018;16:e645-e653.
- 5 43. Khosrow-Khavar F, Filion KB, Bouganim N, Suissa S and Azoulay L. Aromatase  
6 Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A  
7 Population-Based Cohort Study. *Circulation*. 2020;141:549-559.
- 8 44. Baselga J, Campone M, Piccart M, Burris HA, 3rd, Rugo HS, Sahmoud T, Noguchi S,  
9 Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T,  
10 Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D and Hortobagyi GN. Everolimus in  
11 postmenopausal hormone-receptor-positive advanced breast cancer. *The New England journal of*  
12 *medicine*. 2012;366:520-9.
- 13 45. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL,  
14 Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A,  
15 Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka  
16 F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I and Group ESCSD. 2018  
17 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39:3021-  
18 3104.
- 19 46. Touyz RM, Herrmann SMS and Herrmann J. Vascular toxicities with VEGF inhibitor  
20 therapies-focus on hypertension and arterial thrombotic events. *J Am Soc Hypertens*.  
21 2018;12:409-425.
- 22 47. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, Dent S,  
23 Ky B, Lyon AR, Lopez-Fernandez T, Fradley MG, Ganatra S, Curigliano G, Mitchell JD,

- 1 Minotti G, Lang NN, Liu JE, Neilan TG, Nohria A, O'Quinn R, Pusic I, Porter C, Reynolds KL,  
2 Ruddy KJ, Thavendiranathan P and Valent P. Defining cardiovascular toxicities of cancer  
3 therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. *Eur Heart J.*  
4 2022;43:280-299.
- 5 48. Li X-Y, Sun J-F and Hu S-Q. The renin-angiotensin system blockers as adjunctive  
6 therapy for cancer: a meta-analysis of survival outcome. *Eur Rev Med Pharmacol Sci.*  
7 2017;21:1375-1383.
- 8 49. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi  
9 M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF,  
10 Tamargo J, Torbicki A, Suter TM and Group ESCSD. 2016 ESC Position Paper on cancer  
11 treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for  
12 Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the  
13 European Society of Cardiology (ESC). *Eur Heart J.* 2016;37:2768-2801.
- 14 50. Beavers CJ, Rodgers JE, Bagnola AJ, Beckie TM, Campia U, Di Palo KE, Okwuosa TM,  
15 Przespolewski ER, Dent S, American Heart Association Clinical Pharmacology C, Cardio-  
16 Oncology Committee of the Council on Clinical C, Council on G, Precision M and the Council  
17 on Peripheral Vascular D. Cardio-Oncology Drug Interactions: A Scientific Statement From the  
18 American Heart Association. *Circulation.* 2022;145:e811-e838.
- 19







**Table 1: Definition of hypertension in patients with cancer and the general adult population according to major guidelines**

<b>IC-OS*</b>	<b>Normal</b>  SBP ≤130 mmHg DBP ≤80 mmHg	<b>Treatment threshold</b>  CVD or ASCVD risk ≥ 10%: SBP ≥130 mmHg and/or DBP ≥80 mmHg  Otherwise: SBP ≥140 mmHg and/or DBP ≥90 mmHg	<b>Cancer therapy holding threshold</b>  SBP ≥180 mmHg and/or DBP ≥110 mmHg	<b>Exaggerated hypertensive response</b> SBP increase >20 mmHg or mean arterial BP increase >15 mmHg	<b>Hypertensive emergency response</b>  Very high BP elevations associated with acute hypertension-mediated organ damage (heart, brain, kidneys), requiring immediate BP reduction to limit target organ damage
<b>NCI CTCAE V5</b>	<b>Grade 1</b> SBP 120-139 mmHg or DBP 80-89 mmHg	<b>Grade 2</b> SBP 140-159 mmHg or DBP 90-99 mmHg if previously WNL.  Change in baseline medical intervention indicated; recurrent or persistent (≥24 hours); symptomatic increase by >20 mmHg (diastolic) or to >140/90 mmHg; monotherapy indicated or initiate	<b>Grade 3</b> SBP ≥160 mmHg or DBP ≥100 mmHg  Medical intervention indicated; > 1 drug or more intensive therapy than previously used indicated	<b>Grade 4</b> Life-threatening complications (i.e., transient, or permanent neurologic deficit, hypertensive crisis).  Urgent intervention indicated	
<b>ACC/AHA 2017</b>	<b>Normal</b> SBP <120 mmHg DBP <80 mmHg	<b>Elevated</b> SBP 120-129 mmHg DBP <80 mmHg	<b>Stage 1</b> SBP 130-139 mmHg DBP 80-90 mmHg	<b>Stage 2</b> SBP >140 mmHg DBP >90 mmHg	<b>Hypertensive Crisis</b> SBP >180 mmHg DBP >120 mmHg

				Drug therapy indicated if ASCVD risk>10%	Drug therapy goal BP<130/80 mmHg	Urgent BP drug therapy initiation
<b>ESC 2018</b>	<b>Optimal</b> SBP<120 mmHg DBP <80 mmHg	<b>Normal</b> SBP 120-129 mmHg DBP 80-84 mmHg	<b>High Normal</b> SBP 130-139 mmHg DBP 85-89 mmHg  Drug therapy considered if ASCVD risk>10% or established CVD, CKD, or DM	<b>Grade 1</b> SBP 140-159 mmHg DBP 90-99 mmHg  First drug therapy target <140/90 mmHg, consider <130/80 mmHg if tolerated, but not SBP <120 mmHg.  In older >65 years, target SBP 130–140 mmHg, and DBP <80 mmHg, initiate with two-drug combination	<b>Grade 2</b> SBP 160-179 mmHg DBP 100-109 mmHg  Drug therapy goal as for Grade 1	<b>Grade 3</b> SBP ≥ 180 mmHg DBP ≥110 mmHg  Urgent drug therapy goal as for Grade 1
<b>ISH</b>	<b>Normal</b> SBP <130 mmHg DBP <85 mmHg		<b>High normal</b> SBP 130-139 mmHg DBP 85-89 mmHg	<b>Grade 1</b> SBP 140-159 mmHg DBP 90-99 mmHg  Drug therapy indicated if ASCVD risk>10% or established CVD, CKD, DM Target BP reduction by 20/10 mmHg, ideally to <140/90 mmHg. Optimal targets: <65 years: 120-130/70-79mmHg ≥65 years: <140/90 mmHg	<b>Grade 2</b> SBP ≥160 mmHg DBP ≥100 mmHg  Immediate drug treatment in all patients	

ACC, American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CAD, coronary artery disease; CKD, chronic kidney disease; CTCAE, Common Terminology Criteria for Adverse Events; CV, cardiovascular; CVD, cardiovascular disease; DBP, diastolic BP; DM, diabetes mellitus; ESC, European Society of Cardiology; HTN, hypertension; IC-OS, International Cardio-Oncology Society; ISH, International Society of Hypertension; NCI, National Cancer Institute; SBP systolic BP. BP values are based on office BP measurement.

\*Definition of hypertension aspect in the cancer patient

Drug Class	Select example drugs	Select malignancies treated	Incidence of hypertension
Vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSPi)	Bevacizumab, Sorafenib Sunitinib Nilotinib Pazopanib Dasatinib Regorafenib Cabozantinib Lenvatinib Ponatinib Axitinib Tivozanib Vandetanib Ramucirumab	Renal, hepatocellular, thyroid, gastrointestinal stromal (GIST)	20%-90% <sup>8</sup>
Bruton's tyrosine kinase inhibitors (TKIs)	Ibrutinib Acalabrutinib	Chronic lymphocytic leukaemia (CLL), Mantle cell lymphoma	71% <sup>19</sup>
Proteasome inhibitors	Carfilzomib Bortezomib	Multiple myeloma	32% <sup>26</sup> 10% <sup>26</sup>
Platinum-based compounds	Cisplatin Carboplatin Oxaliplatin	Mesothelioma <sup>†</sup> , testicular, bladder, gynecological, colorectal, and lung cancers <sup>†</sup>	53% <sup>30</sup>
Alkylating agents	Cyclophosphamide Busulfan Ifosfamide	Hematologic and solid organ malignancies	36% in adults <sup>10</sup> 58% in children <sup>10</sup> 15% in children <sup>34</sup>
Calcineurin inhibitors (CNIs)	Tacrolimus Cyclosporin	After stem cell transplantation	30%-60% <sup>39</sup>
Serine/threonine-protein kinase B-Raf/ mitogen-activated extracellular signal-regulated kinase (BRAF/MEK) inhibitors	Vemurafenib Dabrafenib Encorafenib Trametinib Binimetinib Cobimetinib	Melanoma, colorectal	19.5%* <sup>18</sup>
Rearranged during transfection (RET) kinase inhibitors	Selpercatinib Pralsetinib	Thyroid, Non-small cell lung cancer	43% <sup>20</sup> 21% <sup>20</sup>
Poly ADP ribose polymerase (PARP) inhibitors	Niraparib	Breast, Ovarian	19% <sup>22</sup>
Androgen receptor blockers	Enzalutamide	Metastatic prostate cancer	11 (5%) <sup>42</sup>
Androgen synthesis inhibitors	Abiraterone Leuprolide	Metastatic prostate cancer Prostate cancer	26 (7%) <sup>42</sup> 15% <sup>8</sup>
Aromatase inhibitors	Anastrozole Letrozole Exemestane	Breast Breast Breast	13 % <sup>43</sup> 8 % <sup>43</sup> 10 % <sup>43</sup>
Mammalian target of rapamycin mTOR inhibitors	Everolimus Sirolimus	Renal cell cancer, breast, pancreatic neuroendocrine tumor (PNET)	13 % (PNET) <sup>8</sup>

**Table 2. Incidence of hypertension induced by different classes of anti-cancer drugs**

\* From systematic review including all drugs

† Denotes malignancies for which treatment is not approved by the Food and Drug Administration (i.e., currently given off-label)